RxDoctor Payments Data

Noemi Benitez Charneco, MD

Cardiology · Mayaguez, PRNPI 1962597203

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.

$746in general payments, 2019–2025

Across 32 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • PBG Puerto Rico LLC$177
  • AstraZeneca$175
  • Medtronic$93
  • Pfizer$84
  • Amgen$60
  • Johnson & Johnson$48
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$72697%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
PBG Puerto Rico LLC10$177
AstraZeneca8$175
Medtronic(2 entities)2$93
Pfizer1$84
Amgen3$60
Johnson & Johnson2$48
Pfizer Pharmaceuticals LLC2$28
Boehringer Ingelheim1$25
Merck1$24
Bayer1$20
E.r. Squibb & Sons, L.L.C.1$13

How this compares

Too few cardiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,711
Medicare patients
32
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$67,955
XareltoRivaroxaban24$13,852
FarxigaDapagliflozin Propanediol12$7,061
Metoprolol Succinate171$2,869
SynthroidLevothyroxine Sodium28$2,224
Rosuvastatin Calcium164$2,080
Omega-3 Acid Ethyl Esters34$1,747
Ezetimibe46$1,473
Losartan Potassium111$1,459
Doxazosin Mesylate39$1,209
Amlodipine Besylate111$901
Irbesartan33$856
Olmesartan Medoxomil44$800
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med17$731
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide15$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$67,955108 claims
Johnson & JohnsonXarelto$48$13,85224 claims
AstraZenecaFarxiga$175$7,06112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other cardiology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →